Skip to main
BCYC

BCYC Stock Forecast & Price Target

BCYC Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 11%
Buy 44%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Bicycle Therapeutics PLC is recognized for its innovative approach to drug development through its unique Bicycle platform, which has the potential to offer safer and more effective treatment options in oncology, particularly with candidates like BT1718 and BT5528. The company’s positioning in the market is strengthened by promising clinical data indicating improved efficacy and tolerability over existing therapies, which may lead to increased adoption and revenue growth, particularly in regions where it derives most of its income, such as the United Kingdom. Investor interest in the firm is bolstered by favorable comparisons of its products' profiles against established therapies, suggesting significant market potential and the opportunity for substantial future sales.

Bears say

Bicycle Therapeutics PLC is facing significant uncertainties regarding its competitive position, particularly with its product candidate zele against established treatments such as Padcev, which has contributed to substantial stock decline. The deprioritization of the BT7480 program indicates challenges within the clinical development of combination therapies, further exacerbating concerns regarding the company's pipeline viability. Additionally, potential adverse regulatory outcomes and delays in trial enrollment pose risks to commercialization timelines, ultimately limiting market potential and impacting investor confidence negatively.

BCYC has been analyzed by 9 analysts, with a consensus rating of Buy. 11% of analysts recommend a Strong Buy, 44% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicycle Therapeutics Plc - ADR (BCYC) Forecast

Analysts have given BCYC a Buy based on their latest research and market trends.

According to 9 analysts, BCYC has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicycle Therapeutics Plc - ADR (BCYC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.